ICER Crosses the Center Line
The admonition to the Institute for Clinical and Economic Review’s Beacon Hill economists should be quite simple: “Stay in your lane.”
Tag: Biologics|Cost Value|ICER|Innovation|Neurological|Prior Authorization|Respiratory
